28th Annual Perspectives in Urology: Point Counterpoint

28th Annual Perspectives in Urology: Point Counterpoint (PCP) is organized by Grand Rounds in Urology (GRU) and will be held from Nov 14 - 16, 2019 at The Scottsdale Plaza Resort, Scottsdale, Arizona, United States of America.

Target Audience:
This activity is designed for and will benefit urologists, medical oncologists, radiation oncologists, primary care physicians, and other healthcare professionals involved in the diagnosis and management of urologic diseases.

Description:
The 28th Annual Perspectives in Urology: Point Counterpoint will bring together leading experts in urology, medical oncology, and radiation oncology to discuss and debate the latest topics in men’s health, general urology, and genitourinary cancers. This annual interactive conference will offer topical lectures, pro/con debates, interesting case presentations, interactive panel discussions, and interactive audience response technology. Topics include nocturia, advanced and M0 prostate cancer, bladder cancer and immunotherapy, upper tract cancer management, renal cell carcinoma, MRI and imaging, and other urologic topics.

The goal of PCP 28 is to address key questions on practice-changing developments in these topics and to examine the next generation in diagnosis and treatment. The conference’s format includes not only didactic lectures, but also debates, point-counterpoint discussion panels, and unique-case presentations.

Learning Objectives:
• Discuss best practices for management of urologic conditions like LUTS, ED, nocturia, prostatitis, and incontinence for improved patient care.
• ?Identify the impact of testosterone on men’s health and the impact of ADT on quality of life.
• ?Assess the expanded use of biomarkers to detect for bladder and prostate cancer.
• ?Evaluate the recent advancements in therapeutic layering and drug sequencing in treating prostate cancer, especially in the M0 space.
• ?Appraise the role of immunotherapy and checkpoint inhibition in treating genitourinary cancers.

Additional details will be posted as soon as they are available.